Literature DB >> 10738937

A histopathological study of lymphoepithelial island formation in labial salivary glands in patients with primary Sjögren's syndrome.

Y Yamamura1, K Onodera, R Ichinohasama, K Ooya.   

Abstract

The proliferative status of lymphoepithelial islands in the labial salivary glands of primary Sjögren's syndrome (pSS) patients was investigated by counting the number of argyrophilic nucleolar organizer regions (AgNORs) in epithelial cells constituting the islands. The islands were classified into four groups and evaluated in terms of total area and three discrete zones of the islands. In each pSS group, the mean AgNOR number per total island epithelial cell nucleus was significantly higher than in control ductal epithelial cells. The zonal AgNOR number fluctuated during the process of island formation but became more uniform as the islands developed. Furthermore, statistically significant trends among the four pSS groups were observed in the ratio of T lymphocytes, B lymphocytes and plasma cells surrounding the islands. The results indicated that the islands are highly proliferative once island formation begins and that zonal island cell proliferation may be associated with the inflammatory cells.

Entities:  

Mesh:

Year:  2000        PMID: 10738937     DOI: 10.1034/j.1600-0714.2000.290302.x

Source DB:  PubMed          Journal:  J Oral Pathol Med        ISSN: 0904-2512            Impact factor:   4.253


  2 in total

1.  Vascular endothelial cell participation in formation of lymphoepithelial lesions (epi-myoepithelial islands) in lymphoepithelial sialadenitis (benign lymphoepithelial lesion).

Authors:  Hamdy Metwaly; Jun Cheng; Hiroko Ida-Yonemochi; Kazufumi Ohshiro; Kai Yu Jen; Ai Ru Liu; Takashi Saku
Journal:  Virchows Arch       Date:  2003-05-22       Impact factor: 4.064

2.  EGF activates PI3K-Akt and NF-kappaB via distinct pathways in salivary epithelial cells in Sjögren's syndrome.

Authors:  Hideki Nakamura; Atsushi Kawakami; Hiroaki Ida; Takehiko Koji; Katsumi Eguchi
Journal:  Rheumatol Int       Date:  2007-07-20       Impact factor: 2.631

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.